Key Points
- Axon CEO Patrick Smith sold 10,000 shares on December 8 at an average price of $551.92 for about $5.52M, trimming his stake by 0.32% to 3,110,997 shares (worth roughly $1.717B) after the sale.
- Axon reported quarterly EPS of $1.17, which missed estimates by $0.46, while revenue grew 30.6% year-over-year to $710.64 million.
- The stock opened at $546.65 (down about 1.2% in the report), carries a market cap of $43.14B and a high P/E (~173), and analysts have a consensus rating of "Moderate Buy" with a $815 price target.
Axon Enterprise, Inc (NASDAQ:AXON - Get Free Report) CEO Patrick Smith sold 10,000 shares of the firm's stock in a transaction on Monday, December 8th. The stock was sold at an average price of $551.92, for a total value of $5,519,200.00. Following the completion of the sale, the chief executive officer directly owned 3,110,997 shares of the company's stock, valued at $1,717,021,464.24. This represents a 0.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Axon Enterprise Stock Down 1.2%
Shares of NASDAQ AXON opened at $546.65 on Wednesday. The company has a debt-to-equity ratio of 0.57, a current ratio of 3.12 and a quick ratio of 2.89. The stock has a market capitalization of $43.14 billion, a PE ratio of 172.99, a P/E/G ratio of 127.04 and a beta of 1.40. Axon Enterprise, Inc has a one year low of $469.24 and a one year high of $885.91. The business's fifty day moving average price is $632.62 and its 200-day moving average price is $717.52.
Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $1.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.63 by ($0.46). The firm had revenue of $710.64 million during the quarter, compared to the consensus estimate of $704.83 million. Axon Enterprise had a net margin of 10.05% and a return on equity of 4.29%. The company's revenue was up 30.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.45 earnings per share. On average, equities research analysts anticipate that Axon Enterprise, Inc will post 5.8 EPS for the current year.
Analyst Upgrades and Downgrades
Several research analysts recently commented on the stock. Zacks Research downgraded shares of Axon Enterprise from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 2nd. Royal Bank Of Canada began coverage on Axon Enterprise in a report on Monday, November 17th. They issued an "outperform" rating and a $860.00 price target for the company. UBS Group decreased their price objective on Axon Enterprise from $840.00 to $610.00 and set a "neutral" rating on the stock in a research note on Wednesday, November 5th. Cowen restated a "buy" rating on shares of Axon Enterprise in a research note on Wednesday, November 5th. Finally, JMP Securities reiterated a "market outperform" rating and set a $825.00 price target on shares of Axon Enterprise in a research report on Monday, September 29th. Fourteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $815.00.
Read Our Latest Report on AXON
Institutional Trading of Axon Enterprise
A number of large investors have recently modified their holdings of the business. Westside Investment Management Inc. raised its stake in Axon Enterprise by 4.8% in the second quarter. Westside Investment Management Inc. now owns 283 shares of the biotechnology company's stock valued at $225,000 after purchasing an additional 13 shares in the last quarter. CVA Family Office LLC increased its holdings in shares of Axon Enterprise by 26.9% in the 2nd quarter. CVA Family Office LLC now owns 66 shares of the biotechnology company's stock worth $55,000 after buying an additional 14 shares during the last quarter. Newbridge Financial Services Group Inc. raised its position in shares of Axon Enterprise by 2.8% during the 2nd quarter. Newbridge Financial Services Group Inc. now owns 508 shares of the biotechnology company's stock valued at $421,000 after buying an additional 14 shares in the last quarter. Vicus Capital lifted its holdings in shares of Axon Enterprise by 3.7% during the 3rd quarter. Vicus Capital now owns 396 shares of the biotechnology company's stock worth $284,000 after acquiring an additional 14 shares during the last quarter. Finally, Evergreen Capital Management LLC grew its position in Axon Enterprise by 3.8% in the second quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company's stock worth $342,000 after acquiring an additional 15 shares in the last quarter. Institutional investors own 79.08% of the company's stock.
Axon Enterprise Company Profile
(
Get Free Report)
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
